SOLICITATION NOTICE
A -- VACCINE ADJUVANT DISCOVERY PROGRAM
- Notice Date
- 12/5/2022 8:19:46 AM
- Notice Type
- Presolicitation
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- BAA-DAIT-75N93022R00022
- Response Due
- 12/20/2022 12:00:00 PM
- Point of Contact
- Maribel Miranda, Phone: 2406695139, Tom Bahrami, Phone: 2406695147
- E-Mail Address
-
maribel.miranda@nih.gov, bahramit@niaid.nih.gov
(maribel.miranda@nih.gov, bahramit@niaid.nih.gov)
- Description
- The purpose of this solicitation is to renew the NIAID Adjuvant Discovery Program that�supports the identification and characterization of novel, effective and safe vaccine adjuvants.�The process of discovery new adjuvants through this program must include each of the�following areas of research: (1) Identification of novel adjuvant candidates using high�throughput (HTS) approaches and validation that lead compounds stimulate human cells; (2)�determination of the mechanism of action of select lead compounds, including the�identification of the receptor(s) the adjuvant candidates work through and/or the cellular signaling pathways they activate; (3) optimization of lead adjuvant candidates through�formulation and medicinal chemistry, guided by structure-activity relationship (SAR) studies;�and (4) verification of the efficacy of lead compounds as vaccine adjuvants in vivo in an animal�model. Offerors are encouraged, but not required, to evaluate lead adjuvant candidates in�model systems of vulnerable populations (e.g., newborns, elderly or immunocompromised�individuals). Lead adjuvant candidates identified under a contract project may also be tested�with different vaccine platforms, including nucleic acid-based vaccines. Not only the shortterm efficacy, but also the durability of the immune response induced by the adjuvanted�vaccine must be evaluated. Research solicited under this acquisition will contribute to the pipeline of new adjuvant leads�that either (a) exploit the natural capacity of the innate immune system to initiate and sustain�effective T and B cell responses and to induce long term immune memory or (b) act directly�on lymphocytes to enhance their response to pathogen-derived antigens. Proposals will be evaluated based on the following technical evaluation criteria: (1) Technical�Plan, (2) Scientific and Technical Personnel, (3) Project Management, and (4) Facilities,�Equipment and Other Resources.� It is anticipated that four to 6 [4-6] cost reimbursement, completion type contracts will be�awarded for a five [5]-year period of performance beginning on or about September 2024. NIAID estimates that the average annual total cost (direct and indirect costs combined) is�$1-2M/yr/award . However, it is anticipated that the total cost for the award(s) may vary�depending upon the scope of the project and the technical objectives of the award(s). The�length of time for which funding is requested should be consistent with the nature and�complexity of the proposed research. In no event shall the period of performance proposed�by an offeror exceed five [5] years. Any responsible offeror may submit a proposal which shall be considered by the�Agency. This BAA will be available electronically on/about 12/20/22, and may be accessed�through SAM.gov (https://sam.gov/content/home). This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile�transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID�electronic Contract Proposal Submission (eCPS) website. Submission of proposals by�facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.nih.gov/ and then click on�""How to Submit.""
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/b7f883b0cd034fb593d2eac480a9ba59/view)
- Record
- SN06534760-F 20221207/221205230102 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |